Table 3.
Haplotype frequencies analysis of NRF2 and the risk of CHB, and LC, and HCC.
| Haplotype | Controls (freq) | CHB (freq) | LC (freq) | HCC (freq) | CHB vs. controls | LC vs. controls | HCC vs. controls | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P OR | OR (95% CI) | P OR | OR (95% CI) | P OR | |||||||
| G-A | 0.226 | 0.218 | 0.182 | 0.170 | 0.953 (0.645–1.410) | 0.810 | 0.762 (0.487–1.193) | 0.234 | 0.700 (0.508–0.965) | 0.028 | ||
| G-G | 0.541 | 0.591 | 0.614 | 0.575 | 1.226 (0.883–1.703) | 0.223 | 1.351 (0.942–1.937) | 0.102 | 1.145 (0.885–1.479) | 0.302 | ||
| T-A | 0.180 | 0.150 | 0.173 | 0.207 | 0.809 (0.519–1.261) | 0.349 | 0.953 (0.599–1.518) | 0.840 | 1.195 (0.864–1.652) | 0.281 | ||
| T-G | 0.053 | 0.040 | 0.031 | 0.048 | 0.750 (0.340–1.656) | 0.476 | 0.567 (0.217–1.483) | 0.242 | 0.907 (0.508–1.620) | 0.742 | ||
freq frequency, CHB chronic hepatitis B, LC liver cirrhosis, HCC hepatocellular carcinoma
Boldfaced values indicate a significant difference.